Detalhe da pesquisa
1.
A niche-dependent myeloid transcriptome signature defines dormant myeloma cells.
Blood
; 134(1): 30-43, 2019 07 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-31023703
2.
Outcomes based on plasma biomarkers in METEOR, a randomized phase 3 trial of cabozantinib vs everolimus in advanced renal cell carcinoma.
BMC Cancer
; 21(1): 904, 2021 Aug 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-34364385
3.
Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomised, open-label, phase 3 trial.
Lancet Oncol
; 17(7): 917-927, 2016 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-27279544
4.
Correlative analyses of RET and RAS mutations in a phase 3 trial of cabozantinib in patients with progressive, metastatic medullary thyroid cancer.
Cancer
; 122(24): 3856-3864, 2016 Dec 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-27525386
5.
Changes in plasma biomarkers following treatment with cabozantinib in metastatic castration-resistant prostate cancer: a post hoc analysis of an extension cohort of a phase II trial.
J Transl Med
; 14: 12, 2016 Jan 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-26762579
6.
Correction to: Outcomes based on plasma biomarkers in METEOR, a randomized phase 3 trial of cabozantinib vs everolimus in advanced renal cell carcinoma.
BMC Cancer
; 21(1): 1023, 2021 Sep 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-34525968
7.
Metabolism and Disposition of Cabozantinib in Healthy Male Volunteers and Pharmacologic Characterization of Its Major Metabolites.
Drug Metab Dispos
; 43(8): 1190-207, 2015 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-26015560
8.
Dual effects of a targeted small-molecule inhibitor (cabozantinib) on immune-mediated killing of tumor cells and immune tumor microenvironment permissiveness when combined with a cancer vaccine.
J Transl Med
; 12: 294, 2014 Nov 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-25388653
9.
Depth of Radiographic Response and Time to Tumor Regrowth Predicts Overall Survival Following Anti-VEGF Therapy in Recurrent Glioblastoma.
Clin Cancer Res
; 29(20): 4186-4195, 2023 10 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-37540556
10.
The design, synthesis, and biological evaluation of potent receptor tyrosine kinase inhibitors.
Bioorg Med Chem Lett
; 22(15): 4979-85, 2012 Aug 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-22765894
11.
Results of a Phase II Placebo-controlled Randomized Discontinuation Trial of Cabozantinib in Patients with Non-small-cell Lung Carcinoma.
Clin Lung Cancer
; 20(2): 74-81.e1, 2019 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-30528315
12.
Inhibition of the T790M gatekeeper mutant of the epidermal growth factor receptor by EXEL-7647.
Clin Cancer Res
; 13(12): 3713-23, 2007 Jun 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-17575237
13.
Circulating Tumor Cell Number as a Response Measure of Prolonged Survival for Metastatic Castration-Resistant Prostate Cancer: A Comparison With Prostate-Specific Antigen Across Five Randomized Phase III Clinical Trials.
J Clin Oncol
; 36(6): 572-580, 2018 02 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-29272162
14.
Volumetric response quantified using T1 subtraction predicts long-term survival benefit from cabozantinib monotherapy in recurrent glioblastoma.
Neuro Oncol
; 20(10): 1411-1418, 2018 09 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-29660005
15.
Baseline pretreatment contrast enhancing tumor volume including central necrosis is a prognostic factor in recurrent glioblastoma: evidence from single and multicenter trials.
Neuro Oncol
; 19(1): 89-98, 2017 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-27580889
16.
Diffusion MRI Phenotypes Predict Overall Survival Benefit from Anti-VEGF Monotherapy in Recurrent Glioblastoma: Converging Evidence from Phase II Trials.
Clin Cancer Res
; 23(19): 5745-5756, 2017 Oct 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-28655794
17.
Cabozantinib Is Active against Human Gastrointestinal Stromal Tumor Xenografts Carrying Different KIT Mutations.
Mol Cancer Ther
; 15(12): 2845-2852, 2016 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-27777285
18.
Cabozantinib inhibits prostate cancer growth and prevents tumor-induced bone lesions.
Clin Cancer Res
; 20(3): 617-30, 2014 Feb 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-24097861
19.
Cabozantinib inhibits growth of androgen-sensitive and castration-resistant prostate cancer and affects bone remodeling.
PLoS One
; 8(10): e78881, 2013.
Artigo
em Inglês
| MEDLINE | ID: mdl-24205338
20.
Reply to C. Ren et al.
J Clin Oncol
; 36(22): 2354-2356, 2018 08 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-29894273